Granahan Investment Management LLC Sells 6,218 Shares of Repligen Corporation $RGEN

Key Points

• Granahan Investment Management LLC has reduced its stake in Repligen Corporation by 5.8%, now holding 101,197 shares valued at approximately $12.9 million.
• Repligen's stock opened at $120.58, with a 52-week range between $102.96 and $182.52, while the company reported $0.37 earnings per share for the latest quarter, missing estimates.
• Institutional investors collectively own 97.64% of Repligen's shares, indicating strong institutional confidence in the company.

Granahan Investment Management LLC decreased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 5.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 101,197 shares of the biotechnology company's stock after selling 6,218 shares during the period. Granahan Investment Management LLC owned approximately 0.18% of Repligen worth $12,876,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stifel Financial Corp increased its position in shares of Repligen by 12.1% in the 4th quarter. Stifel Financial Corp now owns 4,939 shares of the biotechnology company's stock valued at $711,000 after buying an additional 535 shares in the last quarter. Algert Global LLC bought a new stake in shares of Repligen in the 4th quarter valued at $844,000. FORA Capital LLC bought a new stake in shares of Repligen in the 4th quarter valued at $203,000. Integral Health Asset Management LLC bought a new stake in shares of Repligen in the 4th quarter valued at $5,758,000. Finally, LRT Capital Management LLC increased its position in shares of Repligen by 6.9% in the 4th quarter. LRT Capital Management LLC now owns 4,274 shares of the biotechnology company's stock valued at $615,000 after buying an additional 276 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Evercore ISI lowered their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company reduced their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Barclays started coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $169.55.

Repligen Stock Up 3.3%

Shares of Repligen stock traded up $3.98 during trading hours on Friday, reaching $124.56. 1,043,994 shares of the company's stock were exchanged, compared to its average volume of 674,243. The company has a 50 day moving average of $121.53 and a two-hundred day moving average of $129.06. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.01 billion, a P/E ratio of -498.22, a P/E/G ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the company earned $0.40 earnings per share. The company's quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.